To determine the therapeutic benefit of tocilizumab in the context of early reperfusion, the Assessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction (ASSAIL-MI) trial was developed [176]. The gene discussed is IL6; the disease is myocardial infarction.